By: Jonathan S. Myers, MD – Moderator; Albert S. Khouri, MD; Tony Realini, MD, MPH; Ruth D. Williams, MD
This course has expired. You can still review the content but course credit is no longer available.
CONTENT SOURCE This continuing medical education (CME)/continuing education (CE) activity captures content from a roundtable discussion that occurred on October 17, 2018. ACTIVITY DESCRIPTION Glaucoma is a leading cause of preventable blindness in the United States, and at least 3 million Americans have a form of this chronic disease. Somewhat asymptomatic, patients may lose more than 40% of their optic nerve fibers before noticing a loss of peripheral vision and seeking medical intervention. Given the rapid increase in the aging American population, as well as increases in groups at high risk for glaucoma (most of which have an age component), the burden of disease related to this condition becomes more significant each year. TARGET AUDIENCE This certified CME/CE activity is designed for optometrists managing glaucoma patients, glaucoma specialists, and general ophthalmologists involved in the management of glaucomatous disorders.
Supported through an educational grant by Aerie Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Discuss the chemical structure and mechanism of action of topical glaucoma medications and evolving neuroprotective medications.
Explain the anti-fibrotic activity in novel drug classes.
Evaluate novel therapeutics and classes of drugs and their potential for enhanced patient compliance.
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In cooperation with Evolve Medical Education LLC, the University of Houston College of Optometry has reviewed and endorsed this course.
Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists.
COPE Course ID: 60039-GL
COPE Event ID: 116570
COPE Expiration date: November 18, 2021
To obtain Credit for this activity, you must read the activity in its entirety and complete the Pretest/ Posttest/Activity Evaluation/Satisfaction Measures Form.
The following faculty/staff members have the following financial relationships with commercial interests:
Jonathan S. Myers, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals; Allergan plc; Glaukos; and MicroOptx. Grant /Research: Aerie Pharmaceuticals; Allergan plc; Carl Zeiss Meditec; Diopsys; Heidelberg Pharma; Novartis; Shire plc; and Sight Sciences. Speaker: Aerie Pharmaceuticals; and Allergan plc.
Albert S. Khouri, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals; Allergan Plc; Glaukos Corporation; and Mobius Therapeutics. Grant/Research Support: Allergan Plc; and NJ Health Foundation. Speaker: Allergan Plc; Bausch + Lomb; and Glaukos.
Tony Realini, MD, MPH, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals; Ellex; iStarMed; New World Medical; Palvella; and ViSci.
Ruth D. Williams, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals; Allergan plc; and EyePoint. Speaker: Aerie Pharmaceuticals.
EDITORIAL SUPPORT DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education, Susan Gallagher-Pecha, director of client services and project management, Evolve; and Michelle Dalton, writer, have no financial
relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Glaucoma Today, CollaborativeEYE, or Aerie Pharmaceuticals.
